PT - JOURNAL ARTICLE AU - Franz, Marlene AU - Kebets, Valeria AU - Berg, Xaver AU - Georgiadis, Foivos AU - Burrer, Achim AU - Brakowski, Janis AU - Kaiser, Stefan AU - Seifritz, Erich AU - Homan, Philipp AU - Walton, Esther AU - van Erp, Theo G. M. AU - Turner, Jessica A. AU - Misic, Bratislav AU - Valk, Sofie L. AU - Yeo, B.T. Thomas AU - Bernhardt, Boris C. AU - Kirschner, Matthias TI - Orbitofrontal thickness and network associations as transdiagnostic signature of negative symptoms along the bipolar-schizophrenia spectrum AID - 10.1101/2024.07.29.24311172 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.29.24311172 4099 - http://medrxiv.org/content/early/2024/07/30/2024.07.29.24311172.short 4100 - http://medrxiv.org/content/early/2024/07/30/2024.07.29.24311172.full AB - Negative symptoms are core features of schizophrenia (SCZ) and also prevalent in bipolar disorder (BD). While orbitofrontal cortex (OFC) alterations have been implicated in the development of negative symptoms, their contributions across disorders remain to be established. Here, we tested how OFC thickness and related network associations relate to severity of negative symptom dimensions across the BD-SCZ spectrum. We included 50 individuals with SCZ, 49 with BD, alongside 122 controls. We assessed amotivation and diminished expression and estimated thickness in the medial and lateral OFC as regions-of-interest as well as 64 other cortical regions. Across BD and SCZ, reduced right lateral and bilateral medial OFC thickness were specifically associated with amotivation, but not diminished expression or other clinical factors. We then generated OFC structural co-variation networks to evaluate how the system-level embedding of the OFC would link to brain-wide cortical maps of negative symptoms. We found that medial OFC co-variation networks spatially correlated with the cortical maps of both negative symptom dimensions. Confirmatory analyses in independent SCZ data from the ENIGMA consortium (n=4,474) revealed similar associations with lateral OFC co-variation networks. Finally, the brain-wide cortical alteration pattern of amotivation was significantly correlated with normative functional and structural white-matter connectivity profiles of the right medial and left lateral OFC as well as adjacent prefrontal and limbic regions. Our work identifies OFC alterations as a possible transdiagnostic signature of amotivation and provide insights into network associations underlying the system-wide cortical alterations of negative symptoms across SCZ and BD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally from the UCLA CNP cohort (University of California, Consortium for Neuropsychiatric Phenomics) and downloaded from the public database OpenfMRI (https://openfmri.org/dataset/ds000030/). The data is described in the study of R.A. Poldrack (Poldrack RA, Congdon E, Triplett W, et al. A phenome-wide examination of neural and cognitive function. Sci Data. 2016;3:160110. doi:10.1038/sdata.2016.110)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors